{
  "docId": "019de076-3901-734c-833f-b5b0e2d3aa41",
  "docSlug": "e86c5f257c7f518e1f9c16c922f96c7d",
  "documentTitle": "Exscientia | Investor Presentation Deck | 76 slides",
  "authorId": "exscientia",
  "authorName": "Exscientia",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 46,
  "pageCount": 76,
  "prevPage": 45,
  "nextPage": 47,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a human anatomy diagram to map specific disease indications to their respective patient counts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-3901-734c-833f-b5b0e2d3aa41/46",
  "deckHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41",
  "deckJsonHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41.json",
  "deckAnchorHref": "/decks/019de076-3901-734c-833f-b5b0e2d3aa41#slide-46",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.28,
        "x": 0.42,
        "y": 0.27
      },
      "kind": "callout",
      "text": "Brain metastases develop in ~50% of SCLC patients; '539, a brain penetrant molecule, may target brain metastases as well as peripheral disease",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fad10b7-586e-4c13-8926-e858f3d33469",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.25,
        "y": 0.23
      },
      "kind": "image",
      "text": "Human anatomy diagram highlighting brain and lung areas",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b07d3714-caf7-4614-ad81-568cab91e0e5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.68,
        "y": 0.46
      },
      "kind": "metric",
      "text": "~45K U.S. Patients Lives Annually",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ca90a91-4578-4a05-91a0-4fab1894771f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "metric",
      "text": "28K Small-cell Lung Cancer Extensive Disease (Stage III / IV)",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35e73bef-7171-4f59-aa0e-c282971e589a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.07,
        "y": 0.38
      },
      "kind": "metric",
      "text": "17K Acute Myeloid Leukaemia",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f7ff2714-e592-4b52-beda-bb3a00e4d2e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.07,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Covers all indications currently being prioritised for IND/CTA-enabling studies. Treatment rate and progression rates based on Cerner Enviza Treatment Architecture Reports 2022; Numbers have been rounded to the nearest 1000 patients per year; 1) Li et al. Int J Gen Med, 2021",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "450cc365-ef85-4d13-80ac-f847c4be896e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.6,
        "x": 0.07,
        "y": 0.13
      },
      "kind": "title",
      "text": "2022 United States incidence for planned patient sub-groups",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b17d25e9-e02d-4fda-a88a-6e10fb71648e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.06
      },
      "kind": "title",
      "text": "LSD1: '539 IND-enabling studies complete",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "454d614c-2eb1-49d7-85a1-e178c9c7a111",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}